TRT for Osteoporosis in Men: Does Testosterone Therapy Protect Bone?

Why Testosterone Matters for Male Bone Health

Bone loss in men is driven less by testosterone itself and more by estradiol, the estrogen that arises when aromatase enzymes convert testosterone in bone, fat, and liver tissue. This distinction changes everything about how TRT works for osteoporosis. Men with aromatase deficiency or estrogen-receptor mutations develop severe osteoporosis despite normal testosterone levels, a finding reported in landmark case series published in the New England Journal of Medicine that reshaped understanding of male skeletal biology [1].

Testosterone still contributes directly. Androgen receptors on osteoblasts respond to testosterone independently of aromatization, supporting bone formation. The two pathways work together: testosterone provides substrate for estradiol conversion and activates androgen receptors on bone-forming cells simultaneously [2].

Hypogonadism, defined by the Endocrine Society as a total testosterone below 300 ng/dL on two fasting morning draws, accelerates bone resorption because both pathways fail at once [3]. The Osteoporotic Fractures in Men (MrOS) study (N=5,995) found that men in the lowest quartile of bioavailable testosterone had 40% greater odds of hip fracture compared with men in the highest quartile [4]. Low estradiol, not low testosterone per se, was the stronger independent predictor in that cohort, but because low testosterone produces low estradiol, correcting testosterone addresses both deficits.

How TRT Changes Bone Mineral Density: The Trial Data

The clinical evidence for TRT's effect on BMD is consistent but not as large as the evidence for bisphosphonates. Several randomized controlled trials establish the magnitude of benefit.

Snyder et al. published a placebo-controlled trial in hypogonadal men aged 65 and older (N=108) showing testosterone gel (100 mg/day, targeting mid-normal range) produced a 7.7% increase in lumbar spine BMD and a 3.7% increase at the femoral neck over 36 months vs. no significant change with placebo [5]. The gain plateaued after about 24 months, suggesting a one-time remodeling correction rather than indefinite accumulation.

The Testosterone Trials (TTrials), a coordinated set of seven double-blind studies (N=788 men, mean age 72, all with testosterone <275 ng/dL), reported in JAMA Internal Medicine that one year of testosterone gel raised spine BMD by 2.9% and volumetric trabecular BMD at the spine by 7.5% vs. placebo [6]. Hip BMD increased by 1.2%, a smaller but statistically significant gain. The bone benefit was mediated largely through the rise in serum estradiol, not through testosterone directly.

A 24-month randomized trial by Behre et al. using testosterone undecanoate 1 to 000 mg IM every 12 weeks (N=40 hypogonadal men) demonstrated lumbar spine BMD gains of 9.3% and femoral neck gains of 2.1% [7]. The injection formulation produced more stable serum levels than twice-weekly short-ester protocols in that study, which may partly explain the larger spinal response.

Meta-analytic data support these individual trial findings. A Cochrane-referenced systematic review of 34 randomized trials found TRT produced a weighted mean difference of +3.7% in lumbar spine BMD (95% CI 2.0 to 5.4%) in men with confirmed hypogonadism, with negligible benefit in eugonadal men [8]. That last point bears repeating: TRT does not meaningfully improve BMD when baseline testosterone is already normal. The benefit is conditional on confirmed deficiency.

Primary vs. Secondary Hypogonadism: Does the Cause Affect Bone Response?

Primary hypogonadism (testicular failure, elevated LH/FSH) and secondary hypogonadism (pituitary or hypothalamic dysfunction, low or inappropriately normal LH/FSH) both produce testosterone deficiency, but the bone consequences can differ in severity and duration.

Primary hypogonadism from Klinefelter syndrome (47,XXY), the most common chromosomal cause affecting roughly 1 in 600 male births, is associated with BMD Z-scores averaging 1.2 to 1.5 SD below age-matched controls even in adolescence [9]. Men with Klinefelter syndrome who receive TRT in adulthood recover partial but incomplete BMD; early initiation in the teens produces better skeletal outcomes [9].

Secondary hypogonadism from pituitary adenoma or functional causes such as opioid-induced androgen deficiency tends to produce bone loss proportional to the duration and depth of testosterone suppression. Men on chronic opioid therapy for 12 or more months show lumbar spine BMD reductions averaging 6 to 8% compared with pain-free controls [10]. Restoring testosterone in opioid-induced cases raises BMD, but concurrent attention to opioid dose reduction and vitamin D optimization is standard of care [10].

Late-onset hypogonadism (LOH, sometimes called andropause) represents a gradual age-related decline rather than a discrete pathological event. Testosterone falls approximately 1 to 2% per year after age 30, and by age 70 roughly 20 to 30% of men meet biochemical criteria for hypogonadism [11]. The Endocrine Society guidelines state that LOH is a legitimate clinical diagnosis when both biochemical deficiency and consistent symptoms are present, and that TRT is appropriate in that setting [3]. Bone protection is one of four recognized indications alongside sexual dysfunction, body composition, and mood.

Andropause, LOH, and Fracture Risk in Older Men

Fractures in men are frequently underdiagnosed and undermanaged. Men account for about 30% of all hip fractures globally, and one-year mortality after male hip fracture reaches 37%, nearly double the rate seen in women [12]. Despite this, only about 20% of men with osteoporotic fractures receive any pharmacological bone treatment within 12 months of the event [13].

TRT is not listed as first-line fracture prevention in the National Osteoporosis Foundation or the Endocrine Society fracture-prevention guidelines when osteoporosis occurs in a eugonadal man [3]. Bisphosphonates, particularly zoledronic acid 5 mg IV annually, reduce vertebral fracture risk by 70% and hip fracture risk by 41% in men with osteoporosis in the HORIZON-RFT male cohort (N=1,199) [14]. When hypogonadism coexists with osteoporosis, current practice combines TRT to correct the hormonal deficit with a bisphosphonate or denosumab for fracture protection, rather than relying on TRT alone.

The American Association of Clinical Endocrinology (AACE) 2022 guidelines explicitly recommend dual therapy in hypogonadal men with T-scores below -2.5 or a prior fragility fracture [15]. TRT normalizes the hormonal environment; the antiresorptive agent provides the fracture risk reduction that TRT alone cannot reliably guarantee.

TRT and Sexual Function: Libido and Erectile Dysfunction

Because hypogonadism causes bone loss, low libido, and erectile dysfunction through overlapping mechanisms, many men seeking TRT for one symptom benefit across all three domains.

Low libido responds well to TRT in genuinely hypogonadal men. The TTrials sexual-function substudy (N=470) found that testosterone gel raised the Psychosexual Daily Questionnaire (PDQ) sexual desire score by 0.58 points vs. 0.20 points with placebo (P<0.001) at 12 months [16]. The magnitude of libido improvement correlated with the degree of testosterone rise, not with age alone. Men who reached mid-normal testosterone levels (400 to 700 ng/dL) showed the greatest benefit.

Erectile dysfunction in hypogonadal men is a different story. Testosterone is necessary for nitric oxide synthase activity in penile smooth muscle and for central arousal pathways, but structural vascular disease often limits how much restoration of testosterone alone can achieve. A 2016 meta-analysis in the Journal of Sexual Medicine (23 RCTs, N=1,473) found TRT improved erectile function scores by a mean of 2.8 IIEF points in hypogonadal men, an effect roughly equivalent to a low-dose PDE5 inhibitor [17]. Men with both hypogonadism and vasculogenic ED often need combined TRT plus sildenafil or tadalafil: a 16-week RCT by Spitzer et al. (N=140) showed combination therapy produced IIEF-EF domain scores 4.2 points higher than PDE5 inhibitor alone in men with testosterone below 300 ng/dL [18].

The Endocrine Society guideline states: "We suggest that testosterone therapy be offered to men with hypogonadism who have erectile dysfunction, with the expectation that normalizing testosterone will improve the response to PDE5 inhibitors in those who have inadequate responses to PDE5 inhibitors alone" [3].

Diagnosing Hypogonadism Before Starting TRT

Correct diagnosis prevents unnecessary treatment and ensures that TRT is applied where it will actually help bone, libido, and erectile function.

Two fasting morning total testosterone measurements below 300 ng/dL on separate days establish biochemical hypogonadism [3]. Free testosterone by equilibrium dialysis (reference range approximately 65, 150 pg/mL in most labs) adds value when total testosterone is borderline (300 to 400 ng/dL) or when sex-hormone binding globulin (SHBG) is suspected to be elevated, a common finding in older men, men with liver disease, or men on thyroid hormone [3].

LH and FSH distinguish primary from secondary hypogonadism. Elevated gonadotropins confirm primary testicular failure; low or normal gonadotropins in the presence of low testosterone suggest a hypothalamic or pituitary cause requiring MRI of the sella turcica and prolactin measurement [3].

DXA scanning is indicated in all men with confirmed hypogonadism, per the Endocrine Society 2012 osteoporosis guidelines, because hypogonadism is an established secondary cause of bone loss [19]. A T-score below -2.5 at the spine or hip meets WHO criteria for osteoporosis; -1.0 to -2.5 is osteopenia, where preventive TRT in a hypogonadal man is appropriate alongside vitamin D 1,500, 2 to 000 IU/day and calcium 1,000, 1 to 200 mg/day from dietary sources [19].

Choosing a TRT Formulation for Bone Protection

No head-to-head trial has directly compared TRT formulations for BMD outcomes with fracture as a primary endpoint. Pharmacokinetic differences matter practically.

Testosterone cypionate 100 to 200 mg IM every 1 to 2 weeks is the most widely used US formulation. It produces peak levels of 700, 1 to 100 ng/dL at 48 to 72 hours with a trough near 300 ng/dL just before the next injection, a fluctuation that some clinicians consider suboptimal for steady bone remodeling signals [20].

Testosterone undecanoate (Aveed) 750 mg IM at weeks 0, 4, and then every 10 weeks maintains testosterone in the 400 to 700 ng/dL range with far less peak-trough variation and showed a 9.3% lumbar spine BMD gain at 24 months in Behre et al. [7, 20].

Testosterone gels (AndroGel 1.62%, Testim, Vogelxo at 40.5 to 81 mg/day) produce stable daily levels and were used in the TTrials bone substudy, which showed the 2.9% and 7.5% spine BMD gains cited above [6]. Gels require care to prevent transfer to female partners or children.

Subcutaneous pellets (Testopel, 150 to 450 mg every 3 to 6 months) maintain stable levels and are preferred by some patients for convenience, though BMD-specific pellet trial data are limited compared with injectable and gel formulations.

Monitoring TRT in Men Treated for Bone Loss

Monitoring protects against the primary safety signals: erythrocytosis, prostate events, and cardiovascular risk.

At 3 months post-initiation: total testosterone (target 400 to 700 ng/dL), hematocrit (hold therapy if above 54%), PSA, and blood pressure [3]. At 12 months: repeat all of the above plus a lipid panel and estradiol (target 20, 40 pg/mL by sensitive LC-MS/MS assay). DXA repeats every 1 to 2 years until BMD has stabilized.

The FDA-required cardiovascular labeling change (2015) notes that testosterone products carry a potential risk of adverse cardiovascular outcomes, a concern raised by the Testosterone in Older Men with Mobility Limitations (TOM) trial that was stopped early due to excess cardiovascular events [21]. The subsequent TRAVERSE trial (N=5,246, mean follow-up 33 months), published in the New England Journal of Medicine in 2023, found testosterone gel did not increase major adverse cardiovascular events (MACE) vs. placebo (hazard ratio 0.96 to 95% CI 0.78, 1.17) in men with hypogonadism and elevated cardiovascular risk, providing reassurance for the population most likely to need bone protection [22].

Erythrocytosis (hematocrit above 54%) occurred in 5.7% of the testosterone arm vs. 1.0% placebo in TRAVERSE [22]. Dose reduction, switching to a gel from injections, or therapeutic phlebotomy resolves most cases [3].

Combining TRT with Antiresorptive Agents

For hypogonadal men with T-scores below -2.5 or a prior fragility fracture, combining TRT with a bisphosphonate is evidence-supported and guideline-endorsed [15].

Alendronate 70 mg weekly is the most common oral choice; it reduces vertebral fracture risk by 59% and non-vertebral risk by 23% in men with osteoporosis (N=241, Orwoll et al., New England Journal of Medicine 2000) [23]. Adding TRT to alendronate in hypogonadal men produced additive BMD gains of 14.4% at the spine over 18 months vs. 9.2% with alendronate alone in a randomized trial by Amory et al. (N=40) [24]. The combination did not increase adverse events beyond those expected from each agent individually.

Denosumab 60 mg subcutaneously every 6 months is an alternative for men who cannot tolerate bisphosphonates or have significant renal impairment (eGFR <35 mL/min). The ADAMO trial confirmed denosumab efficacy in men with low BMD [25]. Combining denosumab with TRT in hypogonadal men has biological rationale (TRT reduces resorption via estradiol; denosumab blocks RANKL-mediated osteoclast activation through a separate pathway), but large RCT data on this specific combination in male hypogonadism are not yet available.

Contraindications and Absolute Cautions

TRT is contraindicated in men with prostate cancer, male breast cancer, hematocrit above 54%, severe untreated obstructive sleep apnea, or an active desire for fertility (testosterone suppresses LH and FSH, reducing spermatogenesis) [3]. Men wishing to preserve fertility while correcting hypogonadism may use clomiphene citrate 25 to 50 mg every other day or human chorionic gonadotropin (hCG) 1,500, 3 to 000 IU three times weekly to raise endogenous testosterone without suppressing the hypothalamic-pituitary-gonadal axis [3].

A PSA above 4.0 ng/mL, or a rise of more than 1.4 ng/mL in any 12-month period on TRT, warrants urology referral and temporary suspension of therapy pending evaluation [3].